Background
==========

Breast invasive carcinoma (BRCA), head and neck cancer (HNSC), and prostate adenocarcinoma (PRAD) are common malignancies in the world, and they remain a major public health problem \[[@b1-medscimonit-26-e923208]\]. The immune infiltrate mechanism is involved in the development of cancers, and immunotherapy has been proven to be a promising strategy in BRCA, HNSC, and PRAD \[[@b2-medscimonit-26-e923208]--[@b4-medscimonit-26-e923208]\]. In BRCA, human epidermal growth factor receptor 2 (HER2) is partially mediated by immune mechanisms and HER2 positive patients respond well to HER2 targeted therapy \[[@b5-medscimonit-26-e923208]\]. For HNSC patients with recurrence and metastases, anti-PD1 antibodies can improve the overall survival (OS) \[[@b6-medscimonit-26-e923208],[@b7-medscimonit-26-e923208]\]. In addition, immuno-therapeutic medicine such as anti-PD1 and anti-CTLA4 show a partial response in PRAD patients \[[@b8-medscimonit-26-e923208]\]. Studies also have indicated that tumor infiltrating neutrophils (TINs) and tumor associated macrophages (TAMs) have effects on survival and therapeutic efficacy in cancer patients \[[@b9-medscimonit-26-e923208],[@b10-medscimonit-26-e923208]\]. Therefore, exploring novel immune-related therapeutic targets is important for facilitating individualization and optimization of cancer patients in treatment.

The special AT-rich sequence binding-protein 1 (SATB1) is one kind of protein that binds to nuclear matrix. SATB1 participates in the mechanisms of chromatin remodeling and regulates gene expression \[[@b11-medscimonit-26-e923208]\]. SATB1 can activate or repress genes by interacting with the PDZ domain of chromatin modifying enzymes \[[@b12-medscimonit-26-e923208]\]. Abnormal expression of SATB1 has been reported in different neoplasms such as glioma, nasopharyngeal, breast, lung, pancreatic, liver, colorectal, kidney, bladder, prostate, ovarian, lymphoma, and so on \[[@b13-medscimonit-26-e923208]\]. SATB1 is essential in T cell maturation and is correlated with thymocyte development and T-helper 2 (Th2) cell activation \[[@b14-medscimonit-26-e923208]\]. A recent study suggested that SATB1 regulates PDCD1 expression during T cell activation and prevents T cell exhaustion, and that dysregulation of this pathway results in anti-tumor immune dysfunction \[[@b15-medscimonit-26-e923208]\]. These findings reveal that SATB1 plays vital roles in tumor infiltrating lymphocytes. However, the specific mechanism of SATB1 in the regulation of tumor immunity remains unclear.

In this study, Oncomine, PrognoScan, Kaplan-Meier plotter (K-M plot), and Gene Expression Profiling Interactive Analysis (GEPIA) were employed to estimate the correlation between the prognosis of cancer patients and SATB1. Additionally, we explored SATB1 expression in immune infiltrating cells in multiple tumors through the Tumor Immune Estimation Resource (TIMER) database. Our results provided insight on SATB1 in tumor-immune interactions in BRCA, HNSC, and PRAD.

Material and Methods
====================

Oncomine analysis
-----------------

We used Oncomine (*<https://www.oncomine.org/>*) and the TIMER site (*<https://cistrome.shinyapps.io/timer/>*) to assess the expression of SATB1 in different cancers \[[@b16-medscimonit-26-e923208],[@b17-medscimonit-26-e923208]\]. The threshold was as follows: fold change=1.5, *P*-value=0.001.

PrognoScan Analysis
-------------------

PrognoScan (*<http://www.abren.net/PrognoScan/>*) was employed to assess the correlation between SATB1 and survival in cancer patients \[[@b18-medscimonit-26-e923208]\]. Cox *P*-value \<0.05 was considered to be statistically significant.

K-M plot analysis
-----------------

The K-M plot (*<http://kmplot.com/>*) is a website which can evaluate the survival of breast, ovarian, lung, and gastric cancer patient samples \[[@b19-medscimonit-26-e923208]\]. Thus, we explored the effect of SATB1 on prognosis in breast, ovarian, lung, and gastric cancer patients via K-M plot.

GEPIA analysis
--------------

Among 33 different types of cancer, GEPIA (*<http://gepia.cancer-pku.cn/>*) was employed to generate survival curves for gene expression. We analyzed gene correlation for given sets of The Cancer Genome Atlas (TCGA) data, and Person's correlation coefficient was also calculated. The SATB1 gene symbol is displayed on the x-axis, and other interested genes are shown on the y-axis.

TIMER analysis
--------------

TIMER is a website tool based on TCGA, which includes 10 897 samples across 32 cancers to evaluate tumor immune infiltration \[[@b17-medscimonit-26-e923208]\]. We analyzed the association between SATB1 and immune infiltration cells, including B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrophils, and dendritic cells (DCs). We looked at the expression level of SATB1 versus tumor purity \[[@b20-medscimonit-26-e923208]\]. Additionally, we also estimated the correlation between SATB1 and biomarkers of tumor infiltrating cells, including markers of CD8+ T cells, T cells (general), B cells, monocytes, TAMs, M1 and M2 macrophages, neutrophils, natural killer (NK) cells, DCs, T-helper 1 (Th1) and Th2 cells, follicular helper T (Tfh) cells, T-helper 17 (Th17) cells, regulatory T cells (Tregs), and exhausted T cells \[[@b21-medscimonit-26-e923208]\]. TIMER can generate scatter plots as well as Spearman's correlation and *P*-value. The SATB1 gene symbol is displayed on the x-axis, and correlated gene symbols are shown on the y-axis. The expression level of genes was adjusted to log2 RSEM. A flow chart of the study design is shown in [Figure 1](#f1-medscimonit-26-e923208){ref-type="fig"}.

Statistical analysis
--------------------

Survival curves were produced via PrognoScan and K-M plot. The results of Oncomine are shown as *P*-value and fold change. K-M plot, PrognoScan, and GEPIA results are shown as hazard ratio (HR), *P*-value or Cox *P*-value. *P*\<0.05 was considered to be statistically significant.

Results
=======

SATB1 expression in various cancers
-----------------------------------

As revealed in [Figure 2A](#f2-medscimonit-26-e923208){ref-type="fig"}, the results from the Oncomine database indicated that the expression of SATB1 was lower in brain, breast, colorectal, head and neck, lung, leukemia, lymphoma, liver, ovarian, melanoma, and sarcoma carcinomas, while SATB1 expression was increased in leukemia and myeloma tissues in some data sets.

To investigate the expression of SATB1 in malignancy, we used RNA-seq data from TCGA. As presented in [Figure 2B](#f2-medscimonit-26-e923208){ref-type="fig"}, SATB1 expression was decreased in bladder urothelial carcinoma (BLCA), BRCA, cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), HNSC, kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), PRAD, rectum adenocarcinoma (READ), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC) tissues. However, SATB1 expression was increased in kidney chromophobe (KICH) tissues.

Prognostic value of SATB1 in cancers
------------------------------------

The effect of SATB1 expression on survival was assessed through PrognoScan; the results are presented in [Table 1](#t1-medscimonit-26-e923208){ref-type="table"}. In particularly, the expression of SATB1 significantly affected prognosis in 7 types of cancers, including breast cancer ([Figure 3A--3E](#f3-medscimonit-26-e923208){ref-type="fig"}), lung cancer ([Figures 3F--3I](#f3-medscimonit-26-e923208){ref-type="fig"}), brain cancer ([Figure 3J](#f3-medscimonit-26-e923208){ref-type="fig"}, [3K](#f3-medscimonit-26-e923208){ref-type="fig"}), prostate cancer ([Figure 3L](#f3-medscimonit-26-e923208){ref-type="fig"}), skin cancer ([Figure 3M](#f3-medscimonit-26-e923208){ref-type="fig"}), bladder cancer ([Figure 3N](#f3-medscimonit-26-e923208){ref-type="fig"}), and eye cancer ([Figure 3O](#f3-medscimonit-26-e923208){ref-type="fig"}). In addition, one cohort (GSE2990) \[[@b22-medscimonit-26-e923208]\] which included 125 samples of BRCA, demonstrated that decreased expression of SATB1 was associated with worse prognosis (relapse-free survival \[RFS\] HR: 0.52, 95% confidence interval \[CI\]: 0.33--0.81, Cox*P*: 0.004; distant metastasis free survival \[DMFS\] HR: 0.53, 95% CI: 0.30--0.96, Cox *P*=0.037).

We also used K-M plot to explore the prognostic effects of SATB1 based on Affymetrix microarrays. As shown in [Figure 4A](#f4-medscimonit-26-e923208){ref-type="fig"} and [4B](#f4-medscimonit-26-e923208){ref-type="fig"}, a lower level of SATB1 was correlate with worse prognosis in BRCA patients (OS HR: 0.72, 95% CI: 0.58--0.89, *P*: 0.0027; RFS HR: 0.77, 95% CI: 0.66--0.90, *P*: 0.0012). In addition, a low level of SATB1 was correlated with poor OS in LUAD (HR: 0.57, 95% CI: 0.49--0.68) ([Figure 4C](#f4-medscimonit-26-e923208){ref-type="fig"}). However, SATB1 had less influence on progression-free survival (PFS) ([Figure 4D](#f4-medscimonit-26-e923208){ref-type="fig"}) in LUAD, and OS and PFS in gastric cancer and ovarian cancer ([Figure 4E--4H](#f4-medscimonit-26-e923208){ref-type="fig"}).

The effect of SATB1 on survival in different cancers was assessed using the GEPIA database. Decreased expression of SATB1 was associated with worse OS and disease-free survival (DFS) in KIRC, LGG, SKCM, and uveal melanoma (UVM); and DFS in PRAD and OS in SARC (sarcoma). Additionally, a high level of SATB1 was associated with worse DFS in STAD (*P*\<0.05) ([Table 2](#t2-medscimonit-26-e923208){ref-type="table"}). These results suggested that SATB1 has the potential to predict prognosis in multiple types of cancers.

Low level of SATB1 impacts the prognosis of BRCA patients with positive estrogen receptor (ER) and mutated TP53
---------------------------------------------------------------------------------------------------------------

To comprehensive understand the potential mechanisms of SATB1 expression in BRCA, we used the K-M plot to explore the association between SATB1 and clinical characteristics of BRCA patients. As shown in [Table 3](#t3-medscimonit-26-e923208){ref-type="table"}, a low level of SATB1 was associated with poor OS and PFS in BRCA patients with positive estrogen receptor (ER) and mutated TP53. Meanwhile, a low level of SATB1 was also associated with PFS in patients with HER2 negative and luminal B of intrinsic subtype, and OS in patients with grade 2 and basal-like 2 of Pietenpol subtype (*P*\<0.05).

SATB1 was associated with tumor immune infiltration in BRCA, HNSC, and PRAD
---------------------------------------------------------------------------

We used the TIMER database to investigate the associations of SATB1 and tumor immune infiltration in 33 types of cancer. As shown [Figures 5](#f5-medscimonit-26-e923208){ref-type="fig"}[](#f6-medscimonit-26-e923208){ref-type="fig"}[](#f7-medscimonit-26-e923208){ref-type="fig"}--[8](#f8-medscimonit-26-e923208){ref-type="fig"}, the results indicate that SATB1 was significantly correlated with tumor purity and B cell infiltration in 16 and 14 types of cancer, respectively. Additionally, SATB1 expression was associated with infiltration of CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and DCs in 11, 19, 25, 16, and 18 types of cancer, respectively.

We further explored the specific cancer type in which SATB1 correlated with tumor immune infiltration. Accordingly, we found that SATB1 was negative related to tumor purity (r=−0.291, *P*=6.71e-21) and positive correlated with infiltration of B cells (r=0.116, *P*=2.83e-04), CD8+ T cells (r=0.251, *P*=1.89e-15), CD4+ T cells (r=0.218,*P*=7.86e-12), macrophages (r=0.151, *P*=1.95e-06), neutrophils (r=0.232, *P*=4.32e-13), and DCs (r=0.189, *P*=4.01e-09) in BRCA ([Figure 5A](#f5-medscimonit-26-e923208){ref-type="fig"}). In addition, SATB1 was negative correlated with tumor purity (r=−0.103, *P*=2.17e-02) and positive correlated with infiltration of B cells (r=0.362, *P*=3.61e-16), CD8+ T cells (r=0.332, *P*=1.26e-13), CD4+ T cells (r=0.455, *P*=7.26e-27), macrophages (r=0.381, *P*=3.75e-18), neutrophils (r=0.216, *P*=1.73e-06), and DCs (r=0.430,*P*=3.97e-23) in HNSC ([Figure 5B](#f5-medscimonit-26-e923208){ref-type="fig"}). Furthermore, SATB1 expression was negative correlated with tumor purity (r=−0.178, *P*=2.52e-04) and positive correlated with infiltration of B cells (r=0.195, *P*=6.81e-05), CD8+ T cells (r=0.382, *P*=6.47e-16), CD4+ T cells (r=0.104, *P*=3.47e-02), macrophages (r=0.281, *P*=5.30e-09), neutrophils (r=0.240, *P*=8.21e-07), and DCs (r=0.267, *P*=3.13e-08) in PRAD ([Figure 5C](#f5-medscimonit-26-e923208){ref-type="fig"}). Our findings indicate that SATB1 is essential in immune cells infiltration in BRAC, HNSC, and PRAD.

Correlation between SATB1 and immune marker sets
------------------------------------------------

We investigated the associations between SATB1 and immune markers of diverse immune cells in BRCA, HNSC, and PRAD through the TIMER database. After adjustments for tumor purity, our findings revealed that SATB1 was significantly related to most immune markers of different immune cells and diverse T cells in BRAC, HNSC, and PRAD ([Figure 9A--9C](#f9-medscimonit-26-e923208){ref-type="fig"}, [Table 4](#t4-medscimonit-26-e923208){ref-type="table"}).

As shown in [Table 4](#t4-medscimonit-26-e923208){ref-type="table"}, we discovered that the expression levels of gene markers of CD8+ T cell, T cells (general), B cells, and neutrophils had significant correlations with SATB1 both in BRAC and HNSC. In addition, the expression levels of gene markers of M1 macrophages and Th2 cells had significant correlations with SATB1 both in HNSC and PRAD. We also confirmed that the expression of gene markers of monocytes, TAMs, M2 macrophages, DCs, Th2 cells, Tfh cells, and Tregs significantly correlated with SATB1 in HNSC. These findings indicated that SATB1 is critical to immune escape in BRCA, HNSC, and PRAD microenvironments.

Discussion
==========

The recognition that immune cells can identify and destroy cancer cells has promoted a tremendous shift in the perception of cancers, and immunotherapies have been shown to have curative effects in tumors which were resistant to regular therapy \[[@b23-medscimonit-26-e923208]\]. SATB1 can reprogram gene expression profiles and cause rapid phenotype changes. Increasingly, studies have demonstrated that SATB1 is essential in deterioration of tumors \[[@b13-medscimonit-26-e923208]\]. In our research, we found that aberrant SATB1 expression was related to prognosis in diverse cancers. Lower SATB1 expression correlated with poor survival in BRCA patients with positive ER and mutated TP53. Additionally, our results indicated that in BRAC, HNSC, and PRAD, the infiltration levels of immune cell and different immune gene markers were related to SATB1 expression. Therefore, our study provides a theoretical basis for understanding the function of SATB1 in tumor progression and its application as a tumor biomarker.

In this study, datasets in Oncomine and TIMER were used to explore the expression of SATB1 and its prognostic value in human cancers. We found SATB1 was differentially expressed between cancer and normal tissues in various malignancies. Oncomine analysis revealed that the expression of SATB1 was reduced in brain, breast, colorectal, head and neck, leukemia, liver, lung, lymphoma, melanoma, ovarian, and sarcoma carcinomas, while SATB1 expression was increased in leukemia and myeloma tissues. However, our findings from TCGA data indicated that SATB1 expression was decreased in BLCA, BRCA, CHOL, COAD, ESCA, HNSC, KIRC, KIRP, LIHC, LUAD, LUSC, PRAD, READ, SKCM, STAD, and UCEC; while SATB1 expression was increased in KICH. The differences of SATB1 expression among different types of cancer in diverse databases might be due to the diversity of biological functions of SATB1 as well as data collection approaches. However, we found consistent correlations between SATB1 and prognosis in breast, colorectal, head and neck, liver, lung, gastric, and sarcoma carcinomas. GEPIA analysis based on TCGA data indicated that lower SATB1 expression was related to a worse prognosis for certain cancer types, such as KIRC, LGG, SKCM, PRAD, SARC, and UVM, while elevated SATB1 expression correlated with a better prognosis in STAD. In addition, K-M plot and PrognoScan analysis indicated decreased SATB1 expression was related to short survival in breast, lung, brain, gastric, ovarian, prostate, skin, bladder, and eye cancer patients. Moreover, depletion of SATB1 led to poor OS and PFS in BRAC patients with positive ER and mutated TP53. Thus, these results demonstrated that SATB1 could be used as a prognostic indicator in multiple types of neoplasms.

Another important finding in our research was that a low level of SATB1 was associated with different levels of immune infiltration in neoplasms, especially in BRAC, HNSC, and PRAD. Our results revealed that the SATB1 expression level had significant positive correlation with infiltration levels of B cells, CD4+ T cells, CD8+ T cells, macrophages, neutrophils, and DCs in BRAC, HNSC, and PRAD. M1 and M2 macrophage markers, such as NOS2, PTGS2, IRF5, CD163, VSIG4, and MS4A4A, showed weak to strong correlations with SATB1 expression, which indicated the regulating function of SATB1 in TAM polarization. Decreased SATB1 expression also was positively associated with the Treg and T cell exhaustion markers, such as FOXP3, CCR8, STAT5B, TGF β, and PD-1 in BRAC, HNSC and PRAD. In addition, significant correlations between SATB1 and the regulation markers of T helper cells, such as Th1, Th2, Tfh, and Th17, were found in BRAC, HNSC, and PRAD. These results suggest that SATB1 is correlated with tumor immune infiltration and plays a vital role in regulation and enrollment of tumor immune infiltrating cells in BRAC, HNSC, and PRAD.

Diverse mechanisms involved in the carcinogenesis, immune infiltration, and prognosis of SATB1 have been investigated. SATB1 has been shown to be aberrantly expressed in different types of cancers \[[@b24-medscimonit-26-e923208]\]. Generally, SATB1 expression has been positively related to tumor size, lymph node metastasis, tumor evolution, and prognosis in most cancer types \[[@b25-medscimonit-26-e923208]--[@b27-medscimonit-26-e923208]\]. A recent study reported that SATB1 regulates PDCD1 expression during T cell activation and prevents T cell exhaustion \[[@b15-medscimonit-26-e923208]\]. Tesone et al. reported that dynamic variations in SATB1 expression were required for the generation and immuno-stimulatory activity of conventional DCs; however, overexpressed SATB1 in differentiated DCs could convert them into pro-inflammatory or tolerogenic cells and prompt malignant transformation \[[@b28-medscimonit-26-e923208]\]. In an *in vivo* experiment, SATB1 knockdown in DCs could reverse the inflammation and carcinogenic activity, and enhance protective immune responses \[[@b28-medscimonit-26-e923208],[@b29-medscimonit-26-e923208]\]. SATB1 also participates in the pathogenesis of cutaneous T-cell lymphoma, and depletion of SATB1 upregulates IL-5 and IL-9 \[[@b30-medscimonit-26-e923208]\]. Moreover, downregulation of SATB1 is involved in the suppressive effects of Tregs, which play a critical role in peripheral tolerance \[[@b31-medscimonit-26-e923208]\].

In this study, there were several limitations. First, the cutoff value varied in the different online databases, which may introduce potential heterogeneity. Second, the number of samples in the different databases was still limited. Thus, in the future, more studies with a large number of samples are needed to provide more reliable evidence to validate the impact of SATB1 on tumor immune infiltration.

Conclusions
===========

In summary, a low level of SATB1 expression was associated with poor survival rates and enhanced the immune infiltration level of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and DCs in various types of cancer, especially in BRAC, HNSC, and PRAD. Decreased SATB1 expression was also associated with the regulation of TAM, Treg, and T cell exhaustion in BRAC, HNSC, and PRAD. Thus, SATB1 possibly plays a vital role in enrollment and regulation of tumor immune infiltration in BRAC, HNSC, and PRAD.
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![The expression of SATB1 in human cancers. (**A**) High or low SATB1 expression in data sets of different cancers in Oncomine database. (**B**) SATB1 expression levels in different tumor types from Tumor Immune Estimation Resource database (\* *P*\<0.05; \*\* *P*\<0.01; \*\*\* *P*\<0.001).](medscimonit-26-e923208-g002){#f2-medscimonit-26-e923208}

![Kaplan-Meier survival curves comparing the increased and decreased expression of SATB1 in different types of cancer in PrognoScan. (**A--E**) Survival curves of DSS, OS, RFS, DFS, and DMFS in breast cancer cohorts \[GSE3494-GPL96 (n=236), GSE9893 (n=155), GSE2990 (n=125), and GSE4922 (n=249)\]. (**F--I**) Survival curves of RFS, OS, and DSS in lung cancer cohorts \[GSE31210 (n=204), Jacob-00182-MSK (n=104), GSE13213 (n=117), and GSE14814 (n=90)\]. (**J, K**) Survival curves of OS in brain cancer cohorts \[GSE4271-GPL96 (n=77), MGH-glioma (n=50)\]. (**L**) Survival curves of OS in prostate cancer cohorts \[GSE16560 (n=281)\]. (**M**) Survival curves of OS in skin cancer cohorts \[GSE19234 (n=38)\]. (**N**) Survival curves of DSS in bladder cancer cohorts \[GSE13507 (n=165)\]. (**O**) Survival curves of DSS in eye cancer cohorts \[GSE22138 (n=63)\]. DSS -- disease-specific survival; OS -- overall survival; RFS -- relapse-free survival; DFS -- disease-free survival; DMFS -- distant metastasis free survival.](medscimonit-26-e923208-g003){#f3-medscimonit-26-e923208}

![Kaplan-Meier survival curves comparing the expression of SATB1 in different types of cancer in Kaplan-Meier plotter database. (**A, B**) OS and RFS of breast cancer (n=1402, n=977). (**C, D**) OS and PFS of lung cancer (n=1145, n=982). (**E, F**) OS and PFS of gastric cancer (n 631, n=522). (**G, H**) OS and PFS of ovarian cancer (n=655, n=1435). OS -- overall survival; RFS -- relapse-free survival; PFS -- progression-free survival.](medscimonit-26-e923208-g004){#f4-medscimonit-26-e923208}

![SATB1 expression is negatively correlated with tumor purity and positively correlated with infiltration levels of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells in BRCA, HNSC, and PRAD. (**A**) Correlation of SATB1 expression with immune infiltration level in BRAC (n=1093). (**B**) Correlation of SATB1 expression with immune infiltration level in HNSC (n=520). (**C**) Correlation of SATB1 expression with immune infiltration level in PRAD (n=497). BRCA -- breast invasive carcinoma; HNSC -- head and neck cancer; PRAD -- prostate adenocarcinoma.](medscimonit-26-e923208-g005){#f5-medscimonit-26-e923208}

![Association of SATB1 expression with immune infiltration levels in (**A**) ACC. (**B**) BLCA. (**C**) CESC. (**D**) CHOL. (**E**) COAD. (**F**) DLBC. (**G**) ESCA. (**H**) GBM. (**I**) KICH. (**J**) KIRC. (**K**) KIRP. ACC -- adenoid cystic carcinoma; BLCA -- bladder urothelial carcinoma; CESC -- cervical squamous cell carcinoma; CHOL -- cholangiocarcinoma; COAD -- colon adenocarcinoma; DLBC -- diffuse large B-cell lymphoma; ESCA -- esophageal carcinoma; GBM -- glioblastoma; KICH -- kidney chromophobe; KIRC -- kidney renal clear cell carcinoma; KIRP -- kidney renal papillary cell carcinoma.](medscimonit-26-e923208-g006){#f6-medscimonit-26-e923208}

![Association of SATB1 expression with immune infiltration levels in (**A**) LGG. (**B**) LIHC. (**C**) LUAD. (**D**) LUSC. (**E**) MESO. (**F**) OV. (**G**) PAAD. (**H**) PCPG. (**I**) READ. (**J**) SARC. (**K**) SKCM. LGG -- low-grade gliomas; LIHC -- liver hepatocellular carcinoma; LUAD -- lung adenocarcinoma; LUSC -- lung squamous cell carcinoma; MESO -- mesothelioma; OV -- ovarian; PAAD -- pancreatic adenocarcinoma; PCPG -- paraganglioma; READ -- rectum adenocarcinoma; SARC -- sarcoma; SKCM -- skin cutaneous melanoma.](medscimonit-26-e923208-g007){#f7-medscimonit-26-e923208}

![Association of SATB1 expression with immune infiltration levels in (**A**) STAD. (**B**) TGCT. (**C**) THCA. (**D**) THYM. (**E**) UCEC. (**F**) UCS. (**G**) UVM. STAD -- stomach adenocarcinoma; TGCT -- testicular germ cell tumors; THCA -- thyroid carcinoma; THYM -- thymoma; UCEC -- uterine corpus endometrial carcinoma; UCS -- uterine carcinosarcoma. UVM -- uveal melanoma.](medscimonit-26-e923208-g008){#f8-medscimonit-26-e923208}

![SATB1 expression correlated with macrophage polarization in BRAC, HNSC, and PRAD. Markers include CD86 and CSF1R of monocytes; CCL2, CD68, and IL10 of TAMs; NOS2, IRF5, and PTGS2 of M1 macrophages; and CD163, VSIG4, and MS4A4A of M2 macrophages. (**A**) Scatterplots of correlations between SATB1 expression and gene markers of M1 macrophages, M2 macrophages, TAMs, and monocytes in BRAC (n=1093). (**B**) Scatterplots of correlations between SATB1 expression and gene markers of M1 macrophages, M2 macrophages, TAMs, and monocytes in HNSC (n=520). (**C**) Scatterplots of correlations between SATB1 expression and gene markers of M1 macrophages, M2 macrophages, TAMs, and monocytes in PRAD (n=497). BRCA -- breast invasive carcinoma; HNSC -- head and neck cancer; PRAD -- prostate adenocarcinoma; TAMs -- tumor associated macrophages.](medscimonit-26-e923208-g009){#f9-medscimonit-26-e923208}

###### 

Relation between SATB1 expression and patient prognosis in different cancer using PrognosScan database.

  Cancer type            Dataset                            Endpoint                           Array type           N         Cox *P*-value         HR \[95% CI\]
  ---------------------- ---------------------------------- ---------------------------------- -------------------- --------- --------------------- ----------------------
  Bladde cancer          GSE5287                            Overall survival                   HG-U133A             30        0.057                 0.55 \[0.30--1.02\]
  GSE13507               Overall survival                   Human-6 v2                         165                  0.151     0.77 \[0.54--1.10\]   
  GSE13507               Disease specific survival          Human-6 v2                         165                  0.018     0.53 \[0.32--0.90\]   
  Blood cancer           GSE12417-GPL96                     Overall survival                   HG-U133A             163       0.299                 1.20 \[0.85--1.68\]
  GSE12417-GPL570        Overall survival                   HG-U133_Plus_2                     79                   0.709     0.90 \[0.51--1.57\]   
  GSE5122                Overall survival                   HG-U133A                           58                   0.763     0.93 \[0.56--1.53\]   
  GSE8970                Overall survival                   HG-U133A                           34                   0.788     0.93 \[0.55--1.57\]   
  GSE4475                Overall survival                   HG-U133A                           158                  0.924     0.98 \[0.71--1.36\]   
  E-TABM-346             Event free survival                HG-U133A                           53                   0.388     0.81 \[0.50--1.31\]   
  E-TABM-346             Overall survival                   HG-U133A                           53                   0.238     0.75 \[0.46--1.21\]   
  GSE16131-GPL96         Overall survival                   HG-U133A                           180                  0.116     0.76 \[0.54--1.07\]   
  GSE2658                Disease specific survival          HG-U133_Plus_2                     559                  0.384     0.92 \[0.76--1.11\]   
  Brain cancer           GSE4271-GPL96                      Overall survival                   HG-U133A             77        0.004                 0.60 \[0.43--0.85\]
  GSE7696                Overall survival                   HG-U133_Plus_2                     70                   0.759     0.95 \[0.70--1.30\]   
  MGH-glioma             Overall survival                   HG-U95A                            50                   0.038     0.70 \[0.50--0.98\]   
  GSE4412-GPL96          Overall survival                   HG-U133A                           74                   0.101     0.69 \[0.44--1.08\]   
  GSE16581               Overall survival                   HG-U133_Plus_2                     67                   0.342     1.86 \[0.52--6.66\]   
  Breast cancer          GSE19615                           Distant metastasis free survival   HG-U133_Plus_2       115       0.311                 0.62 \[0.25--1.56\]
  GSE3143                Overall survival                   HG-U95A                            158                  0.405     1.19 \[0.79--1.78\]   
  GSE7849                Disease free survival              HG-U95A                            76                   0.857     1.05 \[0.59--1.88\]   
  GSE12276               Relapse free survival              HG-U133_Plus_2                     204                  0.604     0.95 \[0.80--1.14\]   
  GSE6532-GPL570         Distant metastasis free survival   HG-U133_Plus_2                     87                   0.463     0.86 \[0.58--1.28\]   
  GSE6532-GPL570         Relapse free survival              HG-U133_Plus_2                     87                   0.463     0.86 \[0.58--1.28\]   
  GSE9195                Distant metastasis free survival   HG-U133_Plus_2                     77                   0.178     1.57 \[0.82--3.01\]   
  GSE9195                Relapse free survival              HG-U133_Plus_2                     77                   0.463     1.24 \[0.69--2.23\]   
  GSE12093               Distant metastasis free survival   HG-U133A                           136                  0.599     0.86 \[0.50--1.49\]   
  GSE11121               Distant metastasis free survival   HG-U133A                           200                  0.910     0.97 \[0.58--1.63\]   
  GSE1378                Relapse free survival              Arcturus 22k                       60                   0.829     0.96 \[0.66--1.39\]   
  GSE1379                Relapse free survival              Arcturus 22k                       60                   0.080     1.80 \[0.93--3.46\]   
  GSE9893                Overall survival                   MLRG Human 21K V12.0               155                  0.001     0.72 \[0.59--0.88\]   
  GSE2034                Distant metastasis free survival   HG-U133A                           286                  0.768     1.05 \[0.77--1.43\]   
  GSE1456-GPL96          Relapse free survival              HG-U133A                           159                  0.326     0.77 \[0.45--1.30\]   
  GSE1456-GPL96          Disease specific survival          HG-U133A                           159                  0.219     0.68 \[0.37--1.26\]   
  GSE1456-GPL96          Overall survival                   HG-U133A                           159                  0.107     0.65 \[0.39--1.10\]   
  GSE7378                Disease free survival              U133AAofAv2                        54                   0.366     0.71 \[0.34--1.50\]   
  E-TABM-158             Relapse free survival              HG-U133A                           117                  0.597     0.91 \[0.65--1.28\]   
  E-TABM-158             Disease specific survival          HG-U133A                           117                  0.702     0.93 \[0.63--1.37\]   
  E-TABM-158             Distant metastasis free survival   HG-U133A                           117                  0.448     0.85 \[0.57--1.28\]   
  E-TABM-158             Overall survival                   HG-U133A                           117                  0.597     0.91 \[0.65--1.28\]   
  GSE3494-GPL96          Disease specific survival          HG-U133A                           236                  \<0.001   0.35 \[0.20--0.62\]   
  GSE4922-GPL96          Disease free survival              HG-U133A                           249                  0.013     0.57 \[0.36--0.89\]   
  GSE2990                Relapse free survival              HG-U133A                           62                   0.198     0.72 \[0.44--1.18\]   
  GSE2990                Distant metastasis free survival   HG-U133A                           125                  0.037     0.53 \[0.30--0.96\]   
  GSE2990                Relapse free survival              HG-U133A                           125                  0.004     0.52 \[0.33--0.81\]   
  GSE2990                Distant metastasis free survival   HG-U133A                           54                   0.339     0.75 \[0.41--1.36\]   
  GSE7390                Distant metastasis free survival   HG-U133A                           198                  0.749     1.04 \[0.80--1.36\]   
  GSE7390                Overall survival                   HG-U133A                           198                  0.886     0.98 \[0.74--1.29\]   
  GSE7390                Relapse free survival              HG-U133A                           198                  0.781     1.03 \[0.83--1.28\]   
  Colorectal cancer      GSE12945                           Disease free survival              HG-U133A             51        0.189                 2.91 \[0.59--14.36\]
  GSE12945               Overall survival                   HG-U133A                           62                   0.914     0.95 \[0.39--2.32\]   
  GSE17536               Disease specific survival          HG-U133_Plus_2                     177                  0.739     1.07 \[0.71--1.61\]   
  GSE17536               Overall survival                   HG-U133_Plus_2                     177                  0.277     1.22 \[0.85--1.73\]   
  GSE17536               Disease free survival              HG-U133_Plus_2                     145                  0.775     1.07 \[0.66--1.74\]   
  GSE14333               Disease free survival              HG-U133_Plus_2                     226                  0.679     1.07 \[0.77--1.50\]   
  GSE17537               Overall survival                   HG-U133_Plus_2                     55                   0.821     1.07 \[0.58--2.00\]   
  GSE17537               Disease free survival              HG-U133_Plus_2                     55                   0.532     1.24 \[0.64--2.40\]   
  GSE17537               Disease specific survival          HG-U133_Plus_2                     49                   0.304     1.54 \[0.68--3.51\]   
  Lung cancer            jacob-00182-CANDF                  Overall survival                   HG-U133A             82        0.503                 0.79 \[0.40--1.56\]
  HARVARD-LC             Overall survival                   HG-U95A                            84                   0.551     1.15 \[0.73--1.81\]   
  jacob-00182-HLM        Overall survival                   HG-U133A                           79                   0.784     0.94 \[0.58--1.50\]   
  MICHIGAN-LC            Overall survival                   HuGeneFL                           86                   0.141     0.51 \[0.21--1.25\]   
  jacob-00182-MSK        Overall survival                   HG-U133A                           104                  0.013     0.48 \[0.26--0.85\]   
  GSE13213               Overall survival                   G4112F                             117                  0.025     0.70 \[0.51--0.96\]   
  GSE31210               Overall survival                   HG-U133_Plus_2                     204                  0.259     0.69 \[0.37--1.31\]   
  GSE31210               Relapse free survival              HG-U133_Plus_2                     204                  \<0.001   0.42 \[0.27--0.66\]   
  jacob-00182-UM         Overall survival                   HG-U133A                           178                  0.189     0.75 \[0.49--1.15\]   
  GSE3141                Overall survival                   HG-U133_Plus_2                     111                  0.775     1.07 \[0.68--1.68\]   
  GSE14814               Overall survival                   HG-U133A                           90                   0.080     0.55 \[0.29--1.07\]   
  GSE14814               Disease specific survival          HG-U133A                           90                   0.029     0.43 \[0.20--0.92\]   
  GSE8894                Relapse free survival              HG-U133_Plus_2                     138                  0.857     1.02 \[0.83--1.25\]   
  GSE4573                Overall survival                   HG-U133A                           129                  0.575     1.22 \[0.62--2.40\]   
  GSE17710               Relapse free survival              Agilent-UNC-custom-4X44K           56                   0.545     0.85 \[0.50--1.44\]   
  GSE17710               Relapse free survival              Agilent-UNC-custom-4X44K           56                   0.332     0.79 \[0.49--1.27\]   
  GSE17710               Overall survival                   Agilent-UNC-custom-4X44K           56                   0.283     0.74 \[0.43--1.28\]   
  GSE17710               Overall survival                   Agilent-UNC-custom-4X44K           56                   0.133     0.68 \[0.41--1.12\]   
  Ovarian cancer         GSE9891                            Overall survival                   HG-U133_Plus_2       278       0.485                 0.94 \[0.80--1.11\]
  DUKE-OC                Overall survival                   HG-U133A                           133                  0.199     0.91 \[0.79--1.05\]   
  GSE8841                Overall survival                   G4100A                             81                   0.203     1.82 \[0.72--4.56\]   
  GSE26712               Overall survival                   HG-U133_Plus_2                     185                  0.269     1.16 \[0.89--1.50\]   
  GSE26712               Disease free survival              HG-U133_Plus_2                     185                  0.248     1.15 \[0.91--1.46\]   
  GSE17260               Progression free survival          G4112A                             110                  0.237     0.89 \[0.73--1.08\]   
  GSE17260               Overall survival                   G4112A                             110                  0.342     0.88 \[0.69--1.14\]   
  GSE14764               Overall survival                   HG-U133A                           80                   0.706     1.07 \[0.75--1.53\]   
  Prostate cancer        GSE16560                           Overall survival                   6K DASL              281       \<0.001               0.66 \[0.54--0.81\]
  Renal cell carcinoma   E-DKFZ-1                           Overall survival                   A-RZPD-20            59        0.525                 1.68 \[0.34--8.29\]
  Skin cancer            GSE19234                           Overall survival                   HG-U133_Plus_2       38        0.021                 0.50 \[0.28--0.90\]
  Soft tissue cancer     GSE30929                           Distant recurrence free survival   HG-U133A             140       0.348                 1.28 \[0.76--2.16\]
  Esophagus cancer       GSE11595                           Overall survival                   CRUKDMF_22K_v1.0.0   34        0.408                 2.56 \[0.28--23.76\]
  Eye cancer             GSE22138                           Distant metastasis free survival   HG-U133_Plus_2       63        \<0.001               0.67 \[0.54--0.84\]
  Head and neck cancer   GSE2837                            Relapse free survival              U133_X3P             28        0.18                  0.81 \[0.59--1.10\]

HR -- hazard ratio; CI -- confidence interval.

###### 

Correlation of SATB1 expression with prognostic values in diverse types of cancer in GEPIA.

  Cancer type   Overall survival   Disease free survival          
  ------------- ------------------ ----------------------- ------ --------
  ACC           0.93               0.85                    1.3    0.47
  BLCA          0.78               0.098                   1.0    0.87
  BRCA          0.95               0.75                    0.99   0.98
  CESC          1.1                0.82                    1.2    0.48
  CHOL          0.61               0.33                    0.45   0.091
  COAD          1.0                1                       1.1    0.73
  DLBC          1.4                0.64                    1.5    0.54
  ESCA          0.81               0.37                    1.2    0.48
  GBM           1.3                0.13                    0.81   0.32
  HNSC          0.82               0.15                    0.73   0.061
  KICH          2.8                0.19                    1.3    0.7
  KIRC          0.58               0.00065                 0.57   0.0026
  KIRP          0.95               0.87                    0.7    0.23
  LAML          1.2                0.44                    1      1
  LGG           0.49               0.00011                 0.64   0.0049
  LIHC          0.91               0.58                    0.94   0.66
  LUAD          0.78               0.095                   1.1    0.6
  LUSC          0.84               0.22                    0.81   0.25
  MESO          0.95               0.8                     0.77   0.34
  OV            1.1                0.27                    1.2    0.19
  PAAD          0.76               0.18                    1.2    0.44
  PCPG          1.8                0.52                    0.39   0.09
  PRAD          1.8                0.36                    0.56   0.0075
  READ          0.77               0.58                    2.1    0.14
  SARC          1.6                0.023                   1.4    0.092
  SKCM          0.54               5.8e-06                 0.72   0.0076
  STAD          0.91               0.56                    1.5    0.039
  TGCT          0.43               0.46                    0.65   0.24
  THCA          0.58               0.28                    1.2    0.48
  THYM          0.28               0.096                   0.58   0.24
  UCEC          1                  0.98                    0.9    0.74
  UCS           0.52               0.062                   0.52   0.076
  UVM           0.13               0.00016                 0.31   0.021

GEPIA -- Gene Expression Profiling Interactive Analysis; HR -- hazard ratio; CI -- confidence interval; ACC -- adenoid cystic carcinoma; BLCA -- bladder urothelial carcinoma; BRCA -- breast invasive carcinoma; CESC -- cervical squamous cell carcinoma; CHOL -- cholangiocarcinoma; COAD -- colon adenocarcinoma; DLBC -- diffuse large B-cell lymphoma; ESCA -- esophageal carcinoma; GBM -- glioblastoma; HNSC -- head and neck cancer; KICH -- kidney chromophobe; KIRC -- kidney renal clear cell carcinoma; KIRP -- kidney renal papillary cell carcinoma; LAML -- lymphoblastic acute myeloid leukemia; LGG -- low-grade gliomas; LIHC -- liver hepatocellular carcinoma; LUAD -- lung adenocarcinoma; LUSC -- lung squamous cell carcinoma; MESO -- mesothelioma; OV -- ovarian; PAAD -- pancreatic adenocarcinoma; PCPG -- paraganglioma; PRAD -- prostate adenocarcinoma; READ -- rectum adenocarcinoma; SARC -- sarcoma; SKCM -- skin cutaneous melanoma; STAD -- stomach adenocarcinoma; TGCT -- testicular germ cell tumors; THCA -- thyroid carcinoma; THYM -- thymoma; UCEC -- uterine corpus endometrial carcinoma; UCS -- uterine carcinosarcoma; UVM -- uveal melanoma.

###### 

Correlation of SATB1 mRNA expression and prognosis in breast cancer with different clinicopathological characters by Kaplan-Meier plotter.

  Clinicopathological characteristics   Overall survival (n=1402)   Progression-free survival (n=3955)                                       
  ------------------------------------- --------------------------- ------------------------------------ -------- ------ ------------------- --------
  **ER status**                                                                                                                              
   Positive                             548                         0.56 (0.39--0.81)                    0.0015   2061   0.8 (0.68--0.94)    0.0062
   Negative                             251                         0.81 (0.51--1.80)                    0.36     801    0.90 (0.72--1.13)   0.38
  **PR status**                                                                                                                              
   Positive                             83                          0.38 (0.10--1.54)                    0.16     589    0.92 (0.65--1.30)   0.62
   Negative                             89                          0.69 (0.27--1.77)                    0.43     549    0.89 (0.66--1.19)   0.42
  **HER2 status**                                                                                                                            
   Positive                             129                         0.86 (0.43--1.73)                    0.68     252    0.17 (0.76--1.81)   0.47
   Negative                             130                         0.85 (0.36--2.01)                    0.71     800    0.70 (0.54--0.91)   0.0078
  **Intrinsic subtype**                                                                                                                      
   Basal                                241                         0.70 (0.43--1.14)                    0.15     618    0.81 (0.63--1.04)   0.092
   Luminal A                            611                         0.79 (0.55--1.12)                    0.19     1933   0.93 (0.78--1.10)   0.39
   Luminal B                            433                         0.71 (0.49--1.03)                    0.071    1149   0.82 (0.68--0.99)   0.043
  **Lymph node status**                                                                                                                      
   Positive                             313                         0.85 (0.58--1.25)                    0.4      3951   0.83 (0.68--1.01)   0.064
   Negative                             594                         0.83 (0.57--1.20)                    0.31     2020   0.93 (0.79--1.10)   0.41
  **Grade**                                                                                                                                  
   1                                    161                         0.57 (0.23--1.40)                    0.21     345    0.96 (0.57--1.61)   0.87
   2                                    387                         0.65 (0.42--1.00)                    0.047    901    0.88 (0.69--1.12)   0.29
   3                                    503                         0.80 (0.58--1.12)                    0.19     903    0.88 (0.71--1.09)   0.25
  **TP53 status**                                                                                                                            
   Mutated                              111                         0.41 (0.18--0.92)                    0.025    188    0.52 (0.32--0.84)   0.0071
   Wild type                            187                         0.70 (0.36--1.34)                    0.28     273    0.98 (0.65--1.50)   0.94
  **Pietenpol subtype**                                                                                                                      
   Basal-like 1                         58                          0.55 (0.18--1.70)                    0.29     171    1.08 (0.67--1.74)   0.74
   Basal-like 2                         38                          4.20 (0.89--19.86)                   0.049    76     0.56 (0.27--1.15)   0.11
   Immunomodulatory                     100                         0.82 (0.32--2.07)                    0.67     203    0.65 (0.36--1.19)   0.16
   Mesenchymal                          73                          0.81 (0.37--1.77)                    0.59     177    0.78 (0.51--1.20)   0.26
   Luminal androgen receptor            83                          0.80 (0.41--1.56)                    0.51     203    1.13 (0.76--1.70)   0.54

HR -- hazard ratio; ER -- estrogen receptor; PR -- progesterone receptor; HER2 -- human epidermal growth factor receptor 2.

###### 

Correlation analysis between SATB1 and relate genes and markers of immune cells in TIMER.

  Description                  Gene marker       BRCA                                                          HNSC                                                          PRAD                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  ---------------------------- ----------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------- -------------------------------------------------------------
  CD8+ T cell                  CD8A              0.231                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.114                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.276                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.248                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.127                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.047                                                         0.339
  CD8B                         0.222             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.117                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.300                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.267                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.012                                                         0.781                                                         −0.039                                                        0.430                                                         
  T cell (general)             CD3D              0.212                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.081                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.199                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.160                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.035                                                         0.437                                                         −0.132                                                        [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}
  CD3E                         0.241             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.108                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.344                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.327                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.046                                                         0.311                                                         −0.042                                                        0.387                                                         
  CD2                          0.225             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.096                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.311                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.287                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.051                                                         0.255                                                         −0.041                                                        0.402                                                         
  B cell                       CD19              0.193                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.078                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.330                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.312                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.003                                                        0.942                                                         −0.178                                                        [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}
  CD79A                        0.234             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.108                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.386                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.375                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.017                                                         0.713                                                         −0.046                                                        0.352                                                         
  Monocyte                     CD86              0.165                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.058                                                         0.067                                                         0.242                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.221                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.030                                                         0.499                                                         −0.069                                                        0.161
  CD115 (CSF1R)                0.225             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.108                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.381                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.376                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.161                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.068                                                         0.167                                                         
  TAM                          CCL2              0.206                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.115                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.343                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.323                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.062                                                         0.168                                                         0.000                                                         0.997
  CD68                         0.090             [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     −0.114                                                        0.660                                                         0.126                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.114                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.064                                                         0.154                                                         0.146                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     
  IL10                         0.169             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.063                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.266                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.253                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.123                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.080                                                         0.102                                                         
  M1 Macrophage                INOS (NOS2)       0.182                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.162                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.372                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.377                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.175                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.115                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}
  IRF5                         −0.002            0.938                                                         −0.073                                                        [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.104                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.100                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.153                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.124                                                        [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       
  COX2 (PTGS2)                 0.384             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.311                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.018                                                         0.689                                                         0.019                                                         0.671                                                         0.308                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.240                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   
  M2 Macrophage                CD163             0.156                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.068                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.284                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.277                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.095                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.019                                                         0.704
  VSIG4                        0.132             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.041                                                         0.198                                                         0.269                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.261                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.004                                                         0.373                                                         0.047                                                         0.337                                                         
  MS4A4A                       0.186             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.070                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.282                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.268                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.004                                                        0.369                                                         −0.127                                                        [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     
  Neutrophils                  CD66b (CEACAM8)   0.076                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.101                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.112                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.105                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.027                                                         0.541                                                         0.023                                                         0.636
  CD11b (ITGAM)                0.155             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.065                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.445                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.428                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.212                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.127                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     
  CCR7                         0.370             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.231                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.493                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.464                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.649                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.566                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   
  Natural killer cell          KIR2DL1           0.384                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.315                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.248                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.242                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.033                                                        0.463                                                         −0.083                                                        0.092
  KIR2DL3                      0.117             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.058                                                         0.068                                                         0.210                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.191                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.044                                                        0.324                                                         −0.017                                                        0.733                                                         
  KIR2DL4                      0.133             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.061                                                         0.056                                                         0.115                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.119                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.084                                                         0.061                                                         0.084                                                         0.087                                                         
  KIR3DL1                      0.168             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.100                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.218                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.209                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.062                                                         0.166                                                         0.035                                                         0.478                                                         
  KIR3DL2                      0.181             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.098                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.302                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.287                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.148                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.134                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     
  KIR3DL3                      0.101             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.065                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.088                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.070                                                         0.123                                                         0.045                                                         0.315                                                         0.053                                                         0.282                                                         
  KIR2DS4                      0.149             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.086                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.115                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.101                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.024                                                         0.586                                                         −0.042                                                        0.387                                                         
  Dendritic cell               HLA-DPB1          0.176                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.027                                                         0.396                                                         0.274                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.252                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.116                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     −0.217                                                        [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}
  HLA-DQB1                     0.142             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.039                                                         0.217                                                         0.193                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.166                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.033                                                         0.466                                                         −0.106                                                        [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       
  HLA-DRA                      0.199             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.072                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.296                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.276                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.053                                                         0.235                                                         −0.047                                                        0.342                                                         
  HLA-DPA1                     0.191             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.056                                                         0.076                                                         0.313                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.291                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.042                                                         0.344                                                         −0.061                                                        0.215                                                         
  Dendritic cell (cintinued)   BDCA-1(CD1C)      0.275                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.161                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.389                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.372                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.201                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.104                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}
  BDCA-4(NRP1)                 0.309             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.235                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.314                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.316                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.034                                                         0.449                                                         0.028                                                         0.566                                                         
  CD11c (ITGAX)                0.184             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.074                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.336                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.330                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.024                                                        0.599                                                         −0.065                                                        0.187                                                         
  Th1                          T-bet (TBX21)     0.230                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.109                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.267                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.237                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.009                                                        0.849                                                         −0.064                                                        0.190
  STAT4                        0.320             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.207                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.267                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.246                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.093                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.021                                                         0.674                                                         
  STAT1                        0.089             [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.039                                                         0.222                                                         0.019                                                         0.670                                                         0.000                                                         0.998                                                         0.281                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.240                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   
  IFN-γ (IFNG)                 0.172             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.080                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.069                                                         0.118                                                         0.028                                                         0.540                                                         0.031                                                         0.489                                                         0.003                                                         0.948                                                         
  TNF-α (TNF)                  0.147             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.111                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.034                                                        0.444                                                         −0.040                                                        0.372                                                         0.070                                                         0.119                                                         −0.028                                                        0.570                                                         
  Th2                          GATA3             −0.308                                                        [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.251                                                        [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.202                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.182                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.196                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.115                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}
  STAT6                        0.022             0.468                                                         −0.023                                                        0.478                                                         0.100                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.105                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.327                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.311                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   
  STAT5A                       0.219             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.141                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.215                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.189                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.072                                                         0.108                                                         −0.004                                                        0.929                                                         
  IL13                         0.085             [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.041                                                         0.196                                                         0.165                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.147                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.053                                                         0.238                                                         −0.030                                                        0.542                                                         
  Tfh                          BCL6              0.081                                                         0.069                                                         0.053                                                         0.096                                                         0.341                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.356                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.131                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.137                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}
  IL21                         0.150             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.083                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.335                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.300                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.015                                                         0.731                                                         0.017                                                         0.732                                                         
  Th17                         STAT3             0.182                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.162                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.320                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.321                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.448                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.412                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}
  IL17A                        0.117             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.078                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       0.151                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.131                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.148                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.033                                                         0.504                                                         
  Treg                         FOXP3             0.187                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.094                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.504                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.506                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.159                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.145                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}
  CCR8                         0.195             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.124                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.565                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.563                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.323                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.294                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   
  STAT5B                       0.247             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.207                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.449                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.437                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.433                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.434                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   
  TGFβ (TGFB1)                 0.097             [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     −0.018                                                        0.568                                                         −0.201                                                        [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.200                                                        [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.085                                                        0.058                                                         −0.119                                                        [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       
  T cell exhaustion            PD-1 (PDCD1)      0.164                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.041                                                         0.194                                                         0.236                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.212                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.054                                                         0.232                                                         0.100                                                         [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}
  CTLA4                        0.211             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.114                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.224                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.196                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.008                                                        0.856                                                         −0.046                                                        0.352                                                         
  LAG3                         0.062             [\*](#tfn5-medscimonit-26-e923208){ref-type="table-fn"}       −0.004                                                        0.900                                                         0.008                                                         0.067                                                         0.005                                                         0.272                                                         −0.152                                                        [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.180                                                        [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   
  TIM-3 (HAVCR2)               0.123             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.014                                                         0.651                                                         0.297                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.280                                                         [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   −0.007                                                        0.120                                                         −0.152                                                        [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     
  GZMB                         0.188             [\*\*\*](#tfn7-medscimonit-26-e923208){ref-type="table-fn"}   0.009                                                         [\*\*](#tfn6-medscimonit-26-e923208){ref-type="table-fn"}     0.063                                                         0.152                                                         0.026                                                         0.564                                                         −0.021                                                        0.644                                                         −0.093                                                        0.057                                                         

TIMER -- Tumor Immune Estimation Resource; BRCA -- breast invasive carcinoma; HNSC -- head and neck squamous cell carcinoma; PRAD -- prostate adenocarcinoma; TAM -- tumor-associated macrophages; Th -- T helper cell; Tfh -- follicular helper T cell; Treg -- regulatory T cell; Cor -- R value of Spearman's correlation; None -- correlation without adjustment. Purity -- correlation adjusted by purity.

*P*\<0.01;

*P*\<0.001;

*P*\<0.0001.
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